# A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

Source: https://onco.cc/trials/nct07359820/  
OnCo record `nct07359820` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Lirafugratinib in advanced solid tumours, run by Elevar Therapeutics, now recruiting.

## Summary

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement is a phase 2 interventional study registered as NCT07359820 by Elevar Therapeutics, with 30 participants planned, started 2026-06-04 and due to reach its primary completion in 2027-09. Interventions recorded: Lirafugratinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07359820
- Phase: 2
- Setting: A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement
- Sponsor: Elevar Therapeutics
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07359820: https://clinicaltrials.gov/study/NCT07359820

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Lirafugratinib](https://onco.cc/drugs/lirafugratinib/)
- companies: [Elevar Therapeutics (HLB)](https://onco.cc/companies/elevar-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07359820.json